A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

An analysis of foodborne outbreak data collection in Austria has found issues with completeness and consistency. A report published by the European Food Safety Authority (EFSA) shared results of a ...

The U.S. Food and Drug Administration announced it is taking action to approve new labeling submitted by the company that includes the addition of ...

In what has become a far too common and troubling occurrence, another whole genome sequenced (WGS) patient — one of the 61 confirmed sick in June 2024 — has come forward long after the outbreak was ...

Supporters say Flock cameras help solve crimes and protect businesses amid police understaffing. Opponents warn the system is a form of mass surveillance and question the security of the data ...

Money market funds in Kenya have quietly transformed from niche capital market products into the most powerful savings engines in the country ...

(NAPSI)—When winter weather comes, the Outdoor Power Equipment Institute (OPEI) encourages home and business owners to review ...

Bearaby may be best known for its iconic weighted blankets, but its first foray in the bedding category may just change that. Available in six gorgeous shades, the recently released Second Skin Sheet ...

The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys ...

The drug information sheets that the FDA requires companies to produce are living documents that get updated with new ...